Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "generics"

207 News Found

Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21


Jubilant Pharmova recovers: ICICI Securities
News | February 13, 2021

Jubilant Pharmova recovers: ICICI Securities

Jubilant announced the completion of demerger of pharma and LSI business into two separate companies


Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
News | February 11, 2021

Indian Pharma market to grow to US$ 130 bn by 2030: Gowda

The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.


Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.


Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr
News | January 23, 2021

Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr

EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business


LASA receives WHO nod for its Ratnagiri unit
Policy | January 13, 2021

LASA receives WHO nod for its Ratnagiri unit

Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.